Clement Hong

Managing the creation and execution of the business strategy for priority health systems, specifically focusing on our cardiovascular portfolio. Orchestrating cross-functional collaboration with customer engagement, medical, market access and patient support services in a non-reporting capacity. Developing and implementing targeted commercial engagement strategies tailored to each health system. Fostering critical relationships with C/D-suite stakeholders, while aligning efforts with cross-functional partners to achieve collective goals.

· Well-versed in key areas: US healthcare landscape including value-based care, health system structure, access navigation and effective team collaboration.

· Accountable for leading strategic initiatives for three commercial regions in collaboration with priority IDNs: Providence Health, Banner Health, and Intermountain Healthcare, amongst other key entities.

Responsible for the commercialization #1 CV branded product, Eliquis. Launched a first-in-class therapy Camzyos for the treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM), an orphan cardiac rare disease. Engaged in multiple projects beyond first-line leadership role including completion of preceptorship to execute brand strategy, led specialty pharmacy distribution initiative and implemented new scope of accountabilities for executive representatives.

• 2020-2022 Winner Circle and 2022 Summit Award Winner for exemplary performance and leadership.
• · One Team/One Goal national award recipient for exemplary matrix partnership in product launch (2022).
• · Partnered with Global Market Access to support Australia Eliquis Brand in their strategic development to address pending competitive generics in fall of 2023.
• · Acted as a brand preceptor by collaboratively leading the enhancement of national proficiencies of the commercial team through our "AskCamzyos" platform from 2023 to 2024.
• · Served a tour of duty, concurrently supporting market access and brand initiatives to bolster Specialty Pharmacy and Electronic Health Record (EHR) projects in 2024.

Launched a first-in-class biologic Andexxa, which received both U.S. Orphan Drug and FDA Breakthrough Therapy designations, for the treatment of life threatening DOAC related bleeds. Motivated, lead and coached sales team and individual contributors to deliver successive levels of achievement in sales and professional development. Functioned as a partner with National Accounts, Medical Affairs, Compliance, Human Resources, and other cross functional teams.

· 2019-Ranked 1 out 4 regionally, 9 out 16 nationally for Andexxa in launch year.

· Secured formulary wins within key systems: Providence, Intermountain and Stanford Health Systems.

· Spearheaded regional discourse on "New Technology Add-On Payment" (NTAP), designated by CMS for innovative technologies in the inpatient setting, to encourage adoption by health-system stakeholders.

Launched a first-in-class biologic Vimizim for the treatment of MPS IVa, an ultra-orphan genetic disease classified as a Lysosomal Storage Disorder. Served as a national trainer to support both national and regional initiatives as well as individual training and development needs. Implemented “Buy and Bill” process with key biologics.

· Launched a first-in-class biologic Brineura for the treatment of Batten disease, an ultra-orphan disease, in addition to several approved rare disease compounds.

· Oversaw the establishment of multiple Point of Care (POC) sites for providing weekly infusion therapy to patients, while assisting with the "buy and bill" process and conducting staff in-service training on product dosing/administration.

· Collaborated with IDN's analytics lead to perform EMR population risk inquiries to compile a potential treatment list using differential diagnostic ICD 9 codes, eventually adopted to scale by brand.

Launched a new novel oral compound Xarelto for the management of thrombosis in both surgical and atrial fibrillation patients in the acute setting. Responsible for the hiring and training of an acute care sales force of ten for product promotion and commercialization. Aligned with internal partners to develop a strategic plan to secure product acceptance with key IDNs and Payors in the NW.

· 2010-2012-Multiple award winner with new product launches as first-line manager.

· 2011-Collaborated with National Accounts Team on national initiative roll-out to leverage Xarelto’s data in ORS to meet “Pay for Performance” metrics related to 30-day post-op readmission rates.

· 2012-Received Marketing Encore Award for innovative approach to optimize ORS outcomes best practices which had a significant impact on commercial team.